Structure-Guided Proteomimetics Disrupt SARS-CoV-2 S-RBD/hACE2 PPI

Study Background and Research Question

Protein–protein interactions (PPIs) are central to myriad biological processes, from signal transduction to immune surveillance. The interaction between the SARS-CoV-2 Spike receptor-binding domain (S-RBD) and human angiotensin-converting enzyme 2 (hACE2) is a prime example of a viral-host PPI with direct clinical relevance, as it mediates viral entry and pathogenesis in COVID-19. However, targeting such interfaces with inhibitors is especially challenging due to their large, shallow contact surfaces. The referenced study (Ferková et al.) sought to overcome these obstacles by designing proteomimetics that can precisely disrupt the S-RBD/hACE2 interface, leveraging advances in structure-guided peptide engineering.

Key Innovation from the Reference Study

The central innovation of this work lies in its use of in silico alanine scanning and high-resolution structural data to guide the rational design of constrained peptidomimetics. By mimicking both the α1-helix (Glu23–Ser44) and a key β-sheet (Thr347–Leu359) of hACE2, the team engineered stapled and macrocyclic peptides that preserve the spatial organization critical for high-affinity binding to the viral S-RBD. The most advanced construct, designated proteomimetic 28, covalently links these two structural motifs, resulting in a synthetic molecule that selectively binds and inhibits the S-RBD/hACE2 interaction. This approach establishes a proof-of-concept for targeting class III PPIs—those with discontinuous, extensive surfaces—using peptide-based scaffolds rather than traditional small molecules.

Methods and Experimental Design Insights

The research strategy began with computational alanine mutagenesis to identify hACE2 residues essential for S-RBD recognition. Structural models guided the selection of α-helical and β-sheet segments, which were then synthesized as stapled and macrocyclized peptides using established peptide chemistry techniques. The α1-helix was stabilized through hydrocarbon stapling, while the β-sheet was cyclized head-to-tail with a D-Pro/L-Pro turn motif. Covalent linkage of these mimetic segments generated the bifunctional proteomimetic 28.

Binding specificity and disruption of the S-RBD/hACE2 interaction were measured using biophysical assays (surface plasmon resonance and cellular entry inhibition with pseudovirus systems). Pharmacokinetic properties were evaluated in lung epithelial cell models, focusing on stability (half-life > 24 h) and permeability (Papp = 2.03 × 10−8 cm·s−1). The study prioritized constructs with selective binding, potent inhibitory activity, and favorable stability profiles for potential intranasal antiviral applications.

Core Findings and Why They Matter

Proteomimetic 28 demonstrated selective binding to the SARS-CoV-2 S-RBD and effectively disrupted the S-RBD/hACE2 PPI in both biophysical and cellular assays. Notably, it inhibited pseudovirus entry with an IC₅₀ of 6.6 μM (Ferková et al.), a significant achievement given the challenging nature of this interface. The construct also displayed high stability in lung epithelial models and low permeability, suggesting suitability for localized, intranasal delivery without rapid systemic absorption.

This work demonstrates that rationally designed, conformationally constrained proteomimetics can overcome the limitations of small-molecule PPI inhibitors—such as poor selectivity and limited potency—when targeting large, discontinuous interfaces. The approach has direct implications for antiviral drug development, particularly for respiratory pathogens where local delivery is advantageous. The findings also highlight the utility of integrating computational design, structural biology, and advanced peptide chemistry for next-generation inhibitor development.

Comparison with Existing Internal Articles

Previous internal analyses, such as "Structure-Guided Proteomimetics Target SARS-CoV-2 S-RBD/hACE2 PPI" and "Structure-Guided Proteomimetics Disrupt SARS-CoV-2 S-RBD/hACE2 PPI", have summarized the foundational concepts of using engineered peptides to disrupt viral-host interactions. The current reference study advances these principles by providing quantitative data on inhibitor potency, selectivity, and stability, and by fully characterizing the dual-mimetic strategy. In contrast, articles focusing on Camostat Mesilate emphasize small-molecule inhibition of proteases involved in airway and fibrosis pathways, such as ENaC and plasmin, illustrating a complementary but mechanistically distinct approach to modulating pathological protein–protein interactions.

Limitations and Transferability

While proteomimetic 28 exhibits promising selectivity and potency in vitro, several limitations must be considered. The study's primary data derive from biophysical and pseudovirus systems, and the pharmacodynamic and immunogenic properties of such constructs in vivo remain to be established. Additionally, the approach depends on high-resolution structural knowledge of the target interface; its transferability to less-characterized PPIs may be limited. Finally, manufacturing scalability and delivery optimization for clinical applications are ongoing challenges for peptide-based therapeutics.

Why this cross-domain matters, maturity, and limitations

This research exemplifies the convergence of antiviral and protein engineering domains, demonstrating how principles from structural biology and chemical biology can be applied to address urgent infectious disease challenges. While the approach is mature in terms of design and in vitro validation, its translation to clinical use will require further optimization and preclinical evaluation. The limitations noted above—particularly regarding in vivo efficacy and manufacturability—define the current boundaries of this strategy. Nonetheless, the proof-of-concept established here sets the stage for broader exploration of proteomimetics in targeting diverse PPIs implicated in viral pathogenesis and beyond.

Protocol Parameters

• Proteomimetic design: Use in silico alanine scanning to identify critical interface residues for mimicry.
• Peptide synthesis: Apply hydrocarbon stapling for α-helices and macrocyclization (D-Pro/L-Pro motif) for β-sheets to enhance conformational stability.
• Binding assays: Employ surface plasmon resonance and pseudovirus entry inhibition to quantify PPI disruption.
• Lung epithelial stability testing: Assess half-life (t_1/2 > 24 h) and permeability (Papp ≈ 2 × 10⁻⁸ cm·s⁻¹) to model potential for intranasal delivery.
• Workflow suggestion: When benchmarking PPI inhibitors, consider orthogonal validation in both cell-free and cell-based formats to verify selectivity and mechanism.

Research Support Resources

For researchers investigating PPI inhibition in airway, fibrosis, or viral entry models, robust small-molecule tools remain essential for dissecting protease-driven mechanisms. Camostat Mesilate (SKU B2082), a potent trypsin-like protease inhibitor, facilitates studies of ENaC function, plasmin activity inhibition, and TGF-β pathway suppression. As reported in multiple workflow articles, Camostat Mesilate supports reliable experimental interrogation of protease-mediated signaling and can be readily solubilized in DMSO or water for in vitro and in vivo applications. For detailed protocols and advanced troubleshooting, see Camostat Mesilate: Applied Workflows for Protease Inhibition. APExBIO provides Camostat Mesilate in multiple package sizes to support diverse research needs.